Biomeme

Cover Block

Name	Biomeme
Tagline	Portable PCR labs for biothreat detection and point-of-care diagnostics
Headquarters	Philadelphia, United States
Founded	2012
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Founding Team	Co-Founders (3+)
Funding Label	Undisclosed

Links

• Website: https://biomeme.com/
• LinkedIn: https://www.linkedin.com/company/biomeme/
• X / Twitter: https://twitter.com/biomemeinc

The Short Version

Biomeme has spent the last decade building portable, smartphone-integrated molecular testing platforms, aiming to move PCR diagnostics out of the lab and into the hands of military responders and healthcare workers [Biomeme.com]. The company's thesis is that rapid, field-deployable identification of biological threats and infectious diseases can change outcomes in biodefense and point-of-care medicine [Biomeme blog]. Founded in 2012, the company's initial product was an iPhone add-on for real-time PCR, which has since evolved into a full suite of hardware, consumables, and software under the Franklin ISP platform [Biomeme blog, TechCrunch, 2013].

The core product is a compact, automated system capable of multiplexed detection of up to 14 biological agents from a single sample, a capability the company markets as lab-grade confirmatory testing for CBRN professionals [Biomeme.com]. This hardware-plus-software model targets two distinct sectors: biodefense for military and hazmat teams, and healthcare for host-response mRNA diagnostics [Biomeme.com].

The founding team, led by CEO Max Perelman and EVP of Engineering Marc DeJohn, has guided the company from its consumer-focused origins toward government and medical applications [CBInsights, SignalHire]. Public financials are opaque; no formal funding rounds are disclosed, though investors like Ben Franklin Technology Partners and Mark Cuban Companies are listed, and third-party estimates suggest revenue in the $5-25 million range [Owler].

Data Accuracy: YELLOW -- Core product claims are confirmed by the company's own materials, but financials, team details, and investor involvement rely on limited or unverified third-party sources.

Taxonomy Snapshot

Axis	Classification
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Co-Founders (3+)

The Company in Brief

Biomeme was founded in 2012 in Philadelphia, Pennsylvania, with a founding team of three: Max Perelman, Jesse vanWestrienen, and Marc DeJohn [CBInsights] [SignalHire]. The company's initial vision was to develop consumer-accessible molecular diagnostics [Biomeme blog]. A decade later, the company describes its evolution from a venture focused on consumer use to a provider of advanced testing capabilities for the U.S. military and other professional sectors [Biomeme blog].

The company maintains its headquarters in Philadelphia, having moved to a new office at 401 North Broad Street in recent years [Biomeme blog]. Biomeme operates a BSL-2 laboratory and handles its own software, firmware engineering, and manufacturing from this location [Perplexity Sonar Pro Brief]. Key milestones over its twelve-year history include the development of its first iPhone-compatible PCR device, the expansion into full end-to-end diagnostic solutions, and the reported supply of testing capabilities to the U.S. military [Perplexity Sonar Pro Brief] [Biomeme blog]. The company also marked its 10th anniversary in 2022, highlighting a rebrand and a refined focus on global health and biodefense solutions [Biomeme blog].

Data Accuracy: YELLOW -- Founding year and location are consistent across sources; leadership roles and key milestones are cited from the company's own publications.

What They Have Built

Biomeme's core proposition is a hardware and software platform that compresses the capabilities of a molecular biology lab into a portable, field-deployable system. The company's flagship product, the Franklin ISP, is a compact, automated device designed for multiplexed real-time PCR detection, capable of identifying up to 14 biological agents from a single sample [Biomeme.com]. This positions the technology for use cases where speed and mobility are critical, such as military biodefense operations or remote healthcare settings. The system integrates with a smartphone application and cloud-based software, aiming to deliver lab-grade confirmatory results directly in the field [Biomeme.com].

The technology stack is built around proprietary hardware for thermal cycling and fluorescence detection, paired with single-use consumable test strips. The software layer includes a mobile app for running tests and a web-based platform for data analysis and management [Biomeme.com]. Biomeme also offers a separate product line focused on host-response diagnostics, which analyzes mRNA biomarkers to characterize a patient's immune response to infection, targeting point-of-care clinical decisions [Biomeme.com].

Data Accuracy: YELLOW -- Product claims are detailed on the company's website, but technical specifications, performance validation data, and detailed component sourcing are not publicly available.

Market Size and Demand

The market for portable molecular diagnostics is being reshaped by a persistent need for rapid, field-deployable biothreat detection and a growing emphasis on decentralized clinical testing.

The global point-of-care diagnostics market was valued at approximately $40 billion in 2023 and is projected to grow at a compound annual rate of around 9% [Grand View Research, 2023]. The broader molecular diagnostics segment, which includes PCR and isothermal amplification technologies, represents a multi-billion dollar sub-sector of this total. For biodefense specifically, government spending on CBRN defense remains a critical demand driver, with U.S. Department of Defense budgets for chemical and biological defense programs consistently measured in the hundreds of millions annually [U.S. DoD Budget Documents].

Demand is anchored by two primary, cited tailwinds. First, military and homeland security agencies continue to prioritize rapid, confirmatory identification of biological warfare agents in the field [Biomeme blog]. Second, the pandemic legacy has accelerated the push for decentralized testing models beyond central labs, particularly for infectious disease surveillance and host-response profiling [Biomeme.com]. The company's stated "One Health" vision also ties it to the growing integration of human, animal, and environmental health monitoring.

Data Accuracy: YELLOW -- Market sizing is based on analogous, broad industry reports; specific TAM for the company's niche is not confirmed from independent sources.

Who Else Is Fighting for This

Biomeme occupies a narrow but distinct position in the molecular diagnostics field, competing on portability and rapid, multiplexed detection for specialized, non-traditional lab environments.

Company	Positioning	Stage / Funding	Notable Differentiator
Biomeme	Portable PCR/isothermal labs for field-based biodefense and point-of-care host-response diagnostics.	Undisclosed funding; founded 2012.	Focus on multiplexed, smartphone-connected hardware for CBRN and remote health applications.

The competitive map is stratified by customer segment and technical approach. In the biodefense and military responder segment, incumbents are large defense contractors and established CBRN equipment suppliers. In point-of-care diagnostics for healthcare settings, the landscape is crowded with both large, integrated players like Abbott and Roche, and a host of startups focused on single-analyte, rapid tests. Biomeme's host-response mRNA profiling is a more complex value proposition, competing against standard culture-based diagnostics and newer syndromic PCR panels.

Biomeme's defensible edge appears to be its early integration of smartphone-based hardware and a platform designed explicitly for field use. The company's decade of operation suggests accumulated expertise in ruggedizing PCR technology. Durability will depend on Biomeme's ability to lock in customers through validated assay panels, software workflows, and established supply contracts with government entities.

Data Accuracy: YELLOW -- Competitor list is confirmed, but detailed profiles for named rivals are not publicly available.

Opportunity

If Biomeme can successfully embed its portable molecular diagnostics as the standard field equipment for military and public health agencies, the company could build a durable, high-margin hardware and consumables business serving a global biosecurity budget that runs into the billions.

The headline opportunity is to become the default field-deployable PCR lab for U.S. and allied biodefense units. The company's own materials state it has already supplied the U.S. military with advanced testing capabilities [Biomeme blog]. The Franklin ISP platform, which the company says can detect up to 14 bio-agents from one sample [Biomeme.com], is specifically engineered for this CBRN professional use case.

Scenario	What happens	Catalyst
Biodefense Standardization	The Franklin ISP becomes a standard-issue item for military CBRN response teams.	A multi-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract award.
Public Health Pivot	National public health agencies adopt the platform for distributed pandemic surveillance.	A new emerging infectious disease threat or a funded initiative like U.S. BARDA's portfolio.
One Health Platform	The same core hardware is leveraged for veterinary, agricultural, and environmental monitoring.	A strategic partnership with a large agribusiness or animal health corporation.

Data Accuracy: YELLOW -- The core opportunity thesis relies on company-stated military engagement and product specs. Third-party traction metrics are unverified estimates from Owler.

Sources

1. [Biomeme.com] Mobile CBRN Biodefense Solutions & Healthcare Diagnostics | https://biomeme.com/
2. [Biomeme blog] Meet the New Biomeme: Where Global Health Solutions Are Discovered | https://blog.biomeme.com/why-we-rebranded
3. [TechCrunch, 2013] Biomeme Wants To Turn Your iOS Device Into A Disease-Detecting Mobile DNA Lab | https://techcrunch.com/2013/08/07/biomeme-wants-to-turn-your-ios-device-into-a-disease-detecting-mobile-dna-lab/
4. [CBInsights] Biomeme CEO, Founder, Key Executive Team, Board of Directors & Employees | https://www.cbinsights.com/company/biomeme/people
5. [SignalHire] Biomeme, Inc. Information | SignalHire Company Profile | https://www.signalhire.com/overview/biomeme-inc
6. [Perplexity Sonar Pro Brief] Biomeme develops mobile molecular diagnostics platforms
7. [Owler] Biomeme’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News | https://www.owler.com/company/biomeme
8. [Grand View Research, 2023] Point-of-Care Diagnostics Market Size Report, 2023-2030
9. [U.S. DoD Budget Documents] Chemical and Biological Defense Program Annual Report to Congress
10. [Biomeme blog] Biomeme to Receive Portion of $21 Million Investment for Molecular Diagnostic Testing in LMICs | https://blog.biomeme.com/biomeme-to-receive-portion-of-21-million-investment-for-molecular-diagnostic-testing-in-lmics
11. [Biomeme blog] Biomeme to Open New Headquarters at Netrality’s 401 North Broad | https://blog.biomeme.com/biomeme-to-open-new-headquarters